Cargando…
Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy
BACKGROUND: Aberrant activation NF-kappaB has been proposed as a mechanism of drug resistance in pancreatic cancer. Recently, inhibition of glycogen synthase kinase-3 has been shown to exert anti-tumor effects on pancreatic cancer cells by suppressing NF-kappaB. Consequently, we investigated whether...
Autores principales: | Mamaghani, Shadi, Patel, Satish, Hedley, David W |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685435/ https://www.ncbi.nlm.nih.gov/pubmed/19405981 http://dx.doi.org/10.1186/1471-2407-9-132 |
Ejemplares similares
-
Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to TRAIL-Induced Apoptosis
por: Mamaghani, Shadi, et al.
Publicado: (2012) -
Nuclear factor kappaB (NF-kappaB) pathway as a therapeutic target in rheumatoid arthritis.
por: Jue, D. M., et al.
Publicado: (1999) -
Nuclear Factor-kappaB in Autoimmunity: Man and Mouse
por: Miraghazadeh, Bahar, et al.
Publicado: (2018) -
Glycogen synthase kinase‐3β participates in acquired resistance to gemcitabine in pancreatic cancer
por: Uehara, Masahiro, et al.
Publicado: (2020) -
NF-kappaB and cytokines in pancreatic acinar cells.
por: Kim, H, et al.
Publicado: (2000)